Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.
Department of Chemical Sciences, University of Naples Federico II, 80126 Naples, Italy.
Inorg Chem. 2024 Aug 26;63(34):16001-16010. doi: 10.1021/acs.inorgchem.4c02456. Epub 2024 Aug 11.
Inorganic medicinal compounds represent a unique and versatile source of potential therapeutics in many diseases and, more recently, in neurodegeneration. Herein we investigated the effects of two η-arene Ru(II) complexes on the self-aggregation processes of several amyloidogenic peptides endowed with different kinetics and primary sequences. The Ru(II) complexes exhibit, around the metal ion, two chlorides, one NHC = -heterocyclic carbene, with a glucosyl and a methyl substituent and separately a hexamethylbenzene, which is named , and one benzene, named . Both complexes were demonstrated to bind monomeric amyloids suppressing aggregation as evidenced in thioflavin T (ThT) binding assays and autofluorescence experiments. Electrospray ionization mass spectrometry (ESI-MS) indicated the formation of direct adducts between amyloid and metal complexes, which determined the marked conformational variation of peptides and a rescue of cellular viability in SH-SY5Y cells. The complex was demonstrated to be a more potent inhibitor of amyloid aggregation compared to likely because of the less hindrance of the arene moiety. The presented data strongly support the in vitro ability of η-arene Ru(II) complexes to suppress amyloid aggregation, providing insights into their potential application as novel therapeutics in neurodegenerative diseases.
无机药物化合物是许多疾病中潜在治疗方法的独特而多功能的来源,最近在神经退行性疾病中也是如此。在此,我们研究了两种 η-芳基 Ru(II) 配合物对具有不同动力学和一级序列的几种淀粉样肽自聚集过程的影响。这两种 Ru(II) 配合物在金属离子周围各有两个氯化物、一个 NHC = -杂环卡宾、一个带有葡萄糖基和甲基取代基的六甲基苯,分别命名为 ,和一个苯,命名为 。实验表明,这两种配合物都能结合单体淀粉样蛋白,抑制聚集,这在硫黄素 T (ThT) 结合测定和自发荧光实验中得到了证明。电喷雾电离质谱 (ESI-MS) 表明淀粉样蛋白和金属配合物之间形成了直接加合物,这决定了肽的显著构象变化,并拯救了 SH-SY5Y 细胞的细胞活力。与 相比, 被证明是一种更有效的淀粉样蛋白聚集抑制剂,这可能是因为芳基部分的阻碍较小。所提供的数据强烈支持 η-芳基 Ru(II) 配合物在体外抑制淀粉样蛋白聚集的能力,为其作为神经退行性疾病的新型治疗方法的潜在应用提供了依据。